Product Name: 3,6-Dichloro-4-isopropylpyridazine (Resmetirom Intermediate)
CAS No.: 107228-51-3
🔬 Product Overview
A critical intermediate in the synthesis of Resmetirom (MGL-3196), a thyroid hormone receptor-β agonist under clinical development for non-alcoholic steatohepatitis (NASH) and metabolic disorders. This compound enables efficient large-scale production of Resmetirom APIs, ensuring high reactivity and compatibility with downstream pharmaceutical processes. Widely used in R&D and commercial manufacturing of thyroid dysfunction therapeutics.
📊 Key Advantages
✅ High Reactivity: ≥98% purity (HPLC/GC-certified), ideal for API synthesis.
⚡ Flexible Packaging: Available in 1kg, 5kg, 25kg bulk quantities; customizable formats.
🔍 Traceable Synthesis: Batch-specific COA with validated synthesis pathways.
💊 Applications
Pharmaceutical Production: Core intermediate for Resmetirom (CAS 920509-32-6), targeting NASH and thyroid-related diseases.
Advanced R&D: Supports development of novel thyroid receptor agonists and metabolic disorder treatments.
📜 Quality Certification
Testing Standards: HPLC, GC, NMR, and mass spectrometry.
Compliance: Meets ICH Q7 and ISO 9001 guidelines for pharmaceutical intermediates.
🌍 Market Trends
Resmetirom’s potential as a first-in-class NASH therapy drives demand for its intermediates. With Resmetirom’s Phase III trials progressing and anticipated FDA approvals (2026-2027), global API production is forecasted to grow at 10% CAGR (2025-2030). Suppliers offering scalable, GMP-compliant intermediates will dominate partnerships with leading pharma firms.
China
